Z79.899: Other long term (current) drug therapy

The ICD-10-CM code for a patient's continuing use of a prescribed medication, including prophylactic use, when no more specific Z79 code names the drug class.

Billable

FY2027

TABLE OF CONTENTS

Example H2

Medical scribe app interface showing a recording waveform, a list of patient notes, and a SOAP note for John Doe.

Stop looking up codes.

Scribe auto-generates them for you.

Try Commure Scribe →

At a glance

Code Family

Z79: Long term (current) drug therapy.

Condition

Long-term drug therapy

HCC Mapping (v28)

None. Z79.4, long term (current) use of insulin, is the only Z79 code that maps in the CMS-HCC v28 crosswalk.

DRG Grouping

MS-DRG 949, Aftercare with CC/MCC, or MS-DRG 950, Aftercare without CC/MCC, in MDC 23 under the FY2027 MS-DRG v44 grouper. That grouping applies only where Z79.899 is the principal diagnosis. Reported as an additional diagnosis it does not change the DRG.

Family Specificity

Thirty-two billable codes in category Z79, divided by pharmacological class, with Z79.899 as the residual for any class the family does not name.

Effective Date

Valid in the FY2026 code set and unchanged in the FY2027 update.

Which Z79 code do I assign?

Category Z79 splits on the pharmacological class of the drug, not on the condition being treated and not on how long the patient has taken it. Work through the named classes first and assign Z79.899 only when none of them covers the drug.

When documentation says…

Code

Long term apixaban, warfarin or rivaroxaban

Z79.01

Long term (current) use of anticoagulants. The note must name the drug and show that the therapy is continuing. An antiplatelet such as clopidogrel goes to Z79.02 instead.

Daily low dose aspirin for cardiovascular prophylaxis

Z79.82

Long term (current) use of aspirin. Z79.0 and Z79.1 each carry an Excludes2 note directing aspirin to this code. Neither the anticoagulant code nor the NSAID code applies.

Continuing insulin for type 2 diabetes

Z79.4

Long term (current) use of insulin. This is the only Z79 code that maps in the CMS-HCC v28 crosswalk. A patient on oral agents alone takes Z79.84, under an Excludes2 note at Z79.4.

Weekly semaglutide or dulaglutide for type 2 diabetes

Z79.85

Long-term (current) use of injectable non-insulin antidiabetic drugs. An oral agent such as metformin goes to Z79.84.

Adalimumab, etanercept or infliximab

Z79.620

Long term (current) use of immunosuppressive biologic. All three drugs appear as inclusion terms under this code, together with monoclonal antibodies.

Daily prednisone for a chronic inflammatory condition

Z79.52

Long term (current) use of systemic steroids. An inhaled steroid goes to Z79.51. Subcategory Z79.6 carries an Excludes2 note for steroids. A patient on a steroid and a biologic takes both codes.

Long term levothyroxine, a statin or a proton pump inhibitor

Z79.899

Other long term (current) drug therapy. No Z79 subcategory names these classes. Assign Z79.899 only after checking the named subcategories against the tabular.

Tabular notes

EXCLUDES2

Category Z79 carries two Excludes2 notes and no Excludes1 note. The first is drug abuse and dependence (F11-F19). The second is drug use complicating pregnancy, childbirth, and the puerperium, coded to the O99.32- subcategory. An Excludes2 note means the patient may carry both conditions. Both codes may be reported when both are documented.

CODE ALSO

Code also any therapeutic drug level monitoring (Z51.81). Z51.81 is the encounter code for a visit whose purpose is a drug level. Z79.899 is the status code for the therapy itself. Z51.81 carries the reciprocal instruction, to code also any long-term (current) drug therapy from category Z79.

FY2027: EFFECTIVE 1 OCTOBER 2026

The FY2027 codes addenda make no addition, deletion or revision in category Z79. The FY2027 tabular addenda change no instructional note in it. Z79.899 is in the FY2027 billable code list and is unchanged in the FY2027 update. In the FY2027 tabular, the sibling Z79.891 is long term (current) use of opiate analgesic. It carries an Excludes2 note for methadone use NOS (F11.9-) and use of methadone for treatment of heroin addiction (the F11.2 codes). Either condition may be reported alongside Z79.891.

Operational & financial impact

Why specificity matters beyond the chart: risk adjustment, DRG assignment and denial exposure all follow from which code is selected.

CMS-HCC v28 (PY2024+)

Z79.899 maps to no HCC in the CMS-HCC v28 model.

Z79.4, long term (current) use of insulin, is the only Z79 code that maps in the v28 crosswalk. It maps to HCC 38, Diabetes with Glycemic, Unspecified, or No Complications.

HCC 38 sits at the foot of the v28 diabetes hierarchy. A documented HCC 35, 36 or 37 in the same collection year supersedes it.

Assigning Z79.899 to a patient on insulin drops a risk-adjustable code from the encounter. The correct selection is Z79.4.

MS-DRG v44 (FY2027)

Z79.899 groups to MS-DRG 949, Aftercare with CC/MCC, or MS-DRG 950, Aftercare without CC/MCC, in MDC 23 under the FY2027 MS-DRG v44 grouper.

That grouping applies only where Z79.899 is the principal diagnosis. As an additional diagnosis it does not change the DRG assignment.

Z79.899 is exempt from present on admission reporting on inpatient claims to general acute care hospitals.

Medicare and commercial payers

A Z79 code states why a monitoring test is medically necessary. A patient on warfarin has an INR drawn under Z51.81 for the encounter, with Z79.01 as the additional diagnosis naming the therapy.

There is no National Coverage Determination specific to long term drug therapy status coding.

WHERE SPECIFICITY IS LOST

Z79.899 is the residual code for category Z79. A named code already exists for anticoagulants, antithrombotics and antiplatelets, NSAIDs, antibiotics, hormonal contraceptives, insulin, inhaled and systemic steroids, immunomodulators, immunosuppressants, chemotherapeutic agents, myelosuppressive agents, agents affecting estrogen receptors, aspirin, bisphosphonates, oral hypoglycemic drugs, injectable non-insulin antidiabetic drugs, hormone replacement therapy and opiate analgesics.

Z79.899 carries no HCC. Of the 31 other billable codes in the family, only Z79.4 maps in the v28 crosswalk.

A record that names a drug class category Z79 covers specifically, reported as Z79.899, is a coding specificity error. Z79.899 is reserved for classes the family does not name.

Documentation checklist to support Z79.899

Chart elements that support code selection and reduce specificity-driven denials.

The name of the medication, recorded in the encounter note rather than only on a standing problem list.

The condition the medication treats, or a statement that the drug is prophylactic.

A statement that the therapy is current, continuing or ongoing.

For a newly started medication, a statement of the intended duration or of the chronic condition it manages.

Confirmation that no Z79 subcategory names the drug class, checked against the tabular before the residual code is assigned.

Where a drug level or laboratory monitoring is the reason for the visit, the order and the result, to support Z51.81 alongside the Z79 code.

For a brief course of medication treating an acute illness, no Z79 code at all. Section I.C.21.c.3 of the Official Guidelines excludes short courses such as antibiotics for acute bronchitis.

For a patient on methadone or buprenorphine for a substance use disorder, the dependence diagnosis rather than a Z79 code. Section I.C.21.c.3 excludes detoxification and maintenance programs.

Where an adverse effect, poisoning or underdosing is documented, the applicable code from T36–T50. Z79.899 describes ongoing use as prescribed, not a problem with the drug.

FAQ

Is Z79.899 a billable code?

Yes. Z79.899 is a valid billable code at full specificity. It is a status code. It describes a circumstance that influences care rather than the reason for the encounter.

What is the difference between Z79.899 and Z51.81?

Z51.81 is the encounter code for a visit whose purpose is therapeutic drug level monitoring. Z79.899 is the status code for the therapy itself. Both may be appropriate on the same claim. The tabular carries reciprocal Code also instructions between Z51.81 and category Z79.

Does Z79.899 map to an HCC?

No. Z79.899 maps to no category in the CMS-HCC v28 model. Z79.4, long term (current) use of insulin, is the only Z79 code that maps in the v28 crosswalk. It maps to HCC 38, Diabetes with Glycemic, Unspecified, or No Complications. HCC 38 is superseded by HCC 35, 36 or 37 when a higher diabetes category is documented in the same collection year.

How long must a medication be taken before a Z79 code applies?

ICD-10-CM sets no number of days or months. Section I.C.21.c.3 of the Official Guidelines describes the purpose of the therapy instead: an extended period as a prophylactic measure, treatment of a chronic condition, or a disease requiring a lengthy course of treatment. AHA Coding Clinic, Second Quarter 2024, page 26, confirms that a newly prescribed antidiabetic drug intended for long term management of a chronic condition may be coded from Z79.

Can Z79.899 be the principal or first-listed diagnosis?

Sequence the reason for the encounter first and report Z79.899 as an additional diagnosis. Z79.899 does not describe a condition treated at the visit. Section I.C.21.c.3 of the Official Guidelines classes Z79 as a status code, reported because the status may affect the course of treatment and its outcome. Submitted as the principal diagnosis on an inpatient claim, Z79.899 groups to MS-DRG 949, Aftercare with CC/MCC, or MS-DRG 950, Aftercare without CC/MCC, under the FY2027 MS-DRG v44 grouper.

Is Z79.899 reported differently on inpatient and outpatient claims?

The code is the same in both settings. On an inpatient claim it is a secondary diagnosis and is exempt from present on admission reporting. On an outpatient claim it supports the medical necessity of monitoring and of medication management, reported after the first-listed reason for the visit. Outpatient coding also requires confirmed therapy. A drug the record lists only as planned or possible is not coded.

When do I code an adverse effect instead of Z79.899?

Code from T36–T50 when the record documents a problem caused by the drug. An adverse effect takes the code for the nature of the adverse effect first, followed by the T36–T50 code with fifth or sixth character 5. A poisoning takes the T36–T50 code first. An underdosing code carries fifth or sixth character 6 and is never reported first (Section I.C.19.e.5.c). Z79.899 describes therapy the patient is taking as prescribed. It may still be reported alongside those codes where the long term therapy continues.

What changed for Z79.899 in FY2027?

Z79.899 is unchanged in the FY2027 update, effective 1 October 2026. The FY2027 addenda make no change in category Z79.

Related codes

Codes in the same family as Z79.899. Only codes with a published page render as links.

Sibling codes in the Z79 family

Z79.01: Long term (current) use of anticoagulants.
Z79.02: Long term (current) use of antithrombotics/antiplatelets.
Z79.1: Long term (current) use of non-steroidal anti-inflammatories (NSAID).
Z79.2: Long term (current) use of antibiotics.
Z79.3: Long term (current) use of hormonal contraceptives.
Z79.4: Long term (current) use of insulin.
Z79.51: Long term (current) use of inhaled steroids.
Z79.52: Long term (current) use of systemic steroids.
Z79.60: Long term (current) use of unspecified immunomodulators and immunosuppressants.
Z79.61: Long term (current) use of immunomodulator.
Z79.620: Long term (current) use of immunosuppressive biologic.
Z79.621: Long term (current) use of calcineurin inhibitor.
Z79.622: Long term (current) use of Janus kinase inhibitor.
Z79.623: Long term (current) use of mammalian target of rapamycin (mTOR) inhibitor.
Z79.624: Long term (current) use of inhibitors of nucleotide synthesis.
Z79.630: Long term (current) use of alkylating agent.
Z79.631: Long term (current) use of antimetabolite agent.
Z79.632: Long term (current) use of antitumor antibiotic.
Z79.633: Long term (current) use of mitotic inhibitor.
Z79.634: Long term (current) use of topoisomerase inhibitor.
Z79.64: Long term (current) use of myelosuppressive agent.
Z79.69: Long term (current) use of other immunomodulators and immunosuppressants.
Z79.810: Long term (current) use of selective estrogen receptor modulators (SERMs).
Z79.811: Long term (current) use of aromatase inhibitors.
Z79.818: Long term (current) use of other agents affecting estrogen receptors and estrogen levels.
Z79.82: Long term (current) use of aspirin.
Z79.83: Long term (current) use of bisphosphonates.
Z79.84: Long term (current) use of oral hypoglycemic drugs.
Z79.85: Long-term (current) use of injectable non-insulin antidiabetic drugs.
Z79.890: Hormone replacement therapy.
Z79.891: Long term (current) use of opiate analgesic.

Additional codes to consider

Codes outside the Z79 family considered alongside Z79.899.

Companion: code alongside when documented

Z51.81: Encounter for therapeutic drug level monitoring, named in the category Z79 Code also note.

Consider instead

Z79.01: Long term (current) use of anticoagulants.
Z79.82: Long term (current) use of aspirin.
Z79.4: Long term (current) use of insulin.
Z79.84: Long term (current) use of oral hypoglycemic drugs.
Z79.85: Long-term (current) use of injectable non-insulin antidiabetic drugs.
Z79.620: Long term (current) use of immunosuppressive biologic.
Z79.52: Long term (current) use of systemic steroids.
Z79.890: Hormone replacement therapy.
T36–T50: Poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances.
F10–F19: Mental and behavioral disorders due to psychoactive substance use.

Sources

All claims on this page derive from government and professional-standards sources.

National Center for Health Statistics. (2026). International classification of diseases, tenth revision, clinical modification (ICD-10-CM) FY2027 files. https://www.cdc.gov/nchs/icd/icd-10-cm/files.html
Centers for Medicare & Medicaid Services and National Center for Health Statistics. (2026). ICD-10-CM official guidelines for coding and reporting FY2027. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2027/ICD-10-CM-October-1-2026-FY27-Guidelines.pdf
Centers for Medicare & Medicaid Services. (2025). 2026 model software/ICD-10 mappings. https://www.cms.gov/medicare/payment/medicare-advantage-rates-statistics/risk-adjustment/2026-model-software-icd-10-mappings
Centers for Medicare & Medicaid Services. (2026). MS-DRG classifications and software, version 44. https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/ms-drg-classifications-and-software